You are here

Producing Novel Biosynthetic Therapeutics from Extreme Microbiomes

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: HDTRA1-16-P-0059
Agency Tracking Number: C152-004-0097
Amount: $143,740.17
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD152-004
Solicitation Number: 2015.2
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-17
Award End Date (Contract End Date): 2017-02-17
Small Business Information
601 Genome Way
Huntsville, AL 35806
United States
DUNS: 614372535
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Anuj Singhal
 (256) 655-4342
Business Contact
 Diana Toh
Phone: (256) 327-9452
Research Institution

Environmental DNA from three extreme samples will be isolated, cloned into a fosmid library (5760 clones) for sequencing. The sequencing datawill cover ~ 240 Megabases and will be assembled into contigs long enough (~ 40 Kilobases) to represent potential biosynthetic gene clusters(BGCs). This data will be compared to BGC databases looking for homology to antibiotic targets of DoD interest and with reasonable expressionprofiles. Subcloning and expression will be performed on BGC clones of interest followed by inhibitory growth assays to prove in vitro antibacterialactivity. The Option period will be used to test the antibacterial cell extracts against DoD pathogens at the Core facility.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government